MedWatch

New study provides good results for Eli Lilly and Boehringer

Jardiance has shown good effect in a study of cardiovascular patients, Eli Lilly, which is developing the drug with Boehringer, reports.

Photo: Mike Blake/REUTERS / X00030

Eli Lilly's diabetes pill Jardiance showed a 21 percent reduction in deaths and hospitalizations of adult patients with heart failure with preserved ejection fraction (HFpEF) compared to a placebo, the pharmaceutical company reported on Friday.

Jardiance is based on the active ingredient Empagliflozin and was invented by Boehringer Ingelheim, which is developing the drug in collaboration with Eli Lilly.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs